Skip to main content
Caplight Logo









SEED Therapeutics

SEED Therapeutics

Private
King of Prussia, PennsylvaniaHealthcare & Life Scienceshttps://www.seedtherapeutics.com/

Last Round

Series A

Extension

Sep 23, 2025

Est. Valuation

$130M

Total Funding Raised

$80M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SEED Therapeutics is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary RITE3™ molecular glue platform to treat diseases in oncology, neurodegeneration, and immunology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular glueTPDtargeted protein degradationprotein degraderundruggable proteinsglue degraderbiotechnologydrug discoverysmall-molecule therapeuticsstructure-based drug designcomputational chemistryPROTAC alternativeubiquitin-proteasome systemoncology drug discoveryneurodegeneration therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SEED Therapeutics Comparables

Compare SEED Therapeutics with similar companies based on industry and business-model similarity.

SEED Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Degron Therapeutics
88%
Plexium
88%
Magnet Biomedicine
88%

SEED Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 23, 2025
Series AAug 6, 2024
Series ANov 13, 2020

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 29, 116% of headcount.

  • Sep 23, 2025

    $30M round led by Eisai.

Recent news

Latest coverage and updates

  • receives_awardAug 17, 2026

    SEED Therapeutics, Inc. received award 2025Prix Galien USA "Best Start-Up" Award on Jul 1st '25.

SEED Therapeutics Filings

Explore SEC and related filing metadata, where available.

SEED Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SEED Therapeutics's valuation, stock price, and market status.

Is SEED Therapeutics a public or private company?

SEED Therapeutics is a private company.

What is the current stock price of SEED Therapeutics?

SEED Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is SEED Therapeutics worth (valuation)?

SEED Therapeutics's valuation is estimated at $130.0M based on funding round data.

Can I buy SEED Therapeutics stock?

SEED Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SEED Therapeutics's last funding round?

SEED Therapeutics's most recent funding round was Series A on August 6, 2024.

Who are the main investors in SEED Therapeutics?

Investor information for SEED Therapeutics is not publicly disclosed.

Will SEED Therapeutics IPO soon?

No public IPO plans have been announced for SEED Therapeutics.

How can I track SEED Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SEED Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersKing of Prussia, Pennsylvania
Employee Range20
Year Founded2019
Last FundingSep 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?